MA46842A - Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8 - Google Patents

Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8

Info

Publication number
MA46842A
MA46842A MA046842A MA46842A MA46842A MA 46842 A MA46842 A MA 46842A MA 046842 A MA046842 A MA 046842A MA 46842 A MA46842 A MA 46842A MA 46842 A MA46842 A MA 46842A
Authority
MA
Morocco
Prior art keywords
methods
treating obesity
angptl8 antibodies
angptl8
antibodies
Prior art date
Application number
MA046842A
Other languages
English (en)
Inventor
Jesper Gromada
Viktoria Gusarova
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA46842A publication Critical patent/MA46842A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA046842A 2016-11-17 2017-11-16 Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8 MA46842A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662423639P 2016-11-17 2016-11-17

Publications (1)

Publication Number Publication Date
MA46842A true MA46842A (fr) 2019-09-25

Family

ID=60655071

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046842A MA46842A (fr) 2016-11-17 2017-11-16 Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8

Country Status (13)

Country Link
US (1) US10442856B2 (fr)
EP (1) EP3541839A1 (fr)
JP (1) JP7133551B2 (fr)
KR (1) KR20190078650A (fr)
CN (1) CN110036029A (fr)
AU (1) AU2017363143B2 (fr)
CA (1) CA3044249A1 (fr)
EA (1) EA201991203A1 (fr)
IL (1) IL266564A (fr)
MA (1) MA46842A (fr)
MX (1) MX382035B (fr)
WO (1) WO2018094112A1 (fr)
ZA (1) ZA201902608B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071139B2 (en) 2014-10-03 2018-09-11 Ngm Biopharmaceuticals, Inc. Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragment
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
CA3080148A1 (fr) 2017-11-10 2019-05-16 Ngm Biopharmaceuticals, Inc. Agents de liaison a angptl8 et leurs methodes d'utilisation
WO2019126194A1 (fr) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Dosage d'angptl8 et ses utilisations
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
JP2022540806A (ja) 2019-07-19 2022-09-20 オンコレスポンス，インク． 免疫調節抗体およびその使用方法
CN110694067A (zh) * 2019-11-06 2020-01-17 首都医科大学附属北京安贞医院 一种抑制血管生成素样蛋白8的物质的应用
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN111690058B (zh) * 2020-03-30 2021-02-05 三优生物医药(上海)有限公司 针对冠状病毒的具有中和活性的抗体及其用途
CN119367545B (zh) * 2025-01-02 2025-04-08 山东第一医科大学(山东省医学科学院) 靶向干预ANGPTL8 mRNA在制备治疗高同型半胱氨酸血症药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040100A1 (fr) 1998-02-09 1999-08-12 Human Genome Sciences, Inc. 45 proteines humaines secretees
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US6930170B2 (en) 1997-06-16 2005-08-16 Genentech, Inc. PRO1184 polypeptides
US7393663B2 (en) 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
NZ523206A (en) 1999-08-31 2004-12-24 Genentech Inc Antibodies that bind to tumor gene sequences
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
US7537903B2 (en) 2007-04-23 2009-05-26 Board Of Regents, The University Of Texas System FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
CA2687746A1 (fr) 2007-05-22 2008-12-18 Novartis Ag Procedes de traitement, de diagnostic et de detection de troubles lies a fgf21
MX2012006397A (es) 2009-12-02 2012-11-30 Amgen Inc PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
US10071139B2 (en) 2014-10-03 2018-09-11 Ngm Biopharmaceuticals, Inc. Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragment
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
LT3439689T (lt) * 2016-04-08 2021-11-10 Regeneron Pharmaceuticals, Inc. Hiperlipidemijos gydymo būdai angptl8 inhibitoriumi ir angptl3 inhibitoriumi

Also Published As

Publication number Publication date
US20180134781A1 (en) 2018-05-17
WO2018094112A1 (fr) 2018-05-24
ZA201902608B (en) 2020-07-29
CN110036029A (zh) 2019-07-19
JP2020500852A (ja) 2020-01-16
EP3541839A1 (fr) 2019-09-25
MX382035B (es) 2025-03-13
AU2017363143A1 (en) 2019-05-23
US10442856B2 (en) 2019-10-15
EA201991203A1 (ru) 2019-10-31
JP7133551B2 (ja) 2022-09-08
AU2017363143B2 (en) 2022-07-28
IL266564A (en) 2019-07-31
KR20190078650A (ko) 2019-07-04
MX2019005651A (es) 2019-11-12
CA3044249A1 (fr) 2018-05-24

Similar Documents

Publication Publication Date Title
MA47206A (fr) Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
MA46842A (fr) Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8
MA51631A (fr) Anticorps anti-pd1 et méthodes de traitement
EP3454945A4 (fr) Inhibiteurs de ash1l et méthodes de traitement au moyen de ceux-ci
EP3723803A4 (fr) Anticorps anti-trem2 et méthodes associées
EP3658589C0 (fr) Anticorps anti-sirp-alpha et méthodes associées
EP3752180A4 (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
LT3988656T (lt) Su nukleosoma sąveikaujančių baltymų domenų panaudojimas tikslinės genomo modifikacijos pagerinimui
EP3478286A4 (fr) Méthodes de traitement du cancer de l'ovaire
MA42924A (fr) Variants optimisés d'anticorps anti-vegf
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
EP3334765A4 (fr) Récepteurs d'antigènes chimériques basés sur des anticorps à domaine unique et leurs méthodes d'utilisation
MA47362A (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
EP3383917A4 (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EP3442996A4 (fr) Méthodes de traitement faisant intervenir des conjugués de chlorotoxine
EP3773632A4 (fr) Méthodes de traitement de glioblastomes exprimant l'egfrviii
EP3313395A4 (fr) Méthodes de traitement d'une inflammation au moyen de composés naturels et/ou d'un régime alimentaire
EP3405191A4 (fr) Méthodes et compositions pour le traitement de l'hyperhidrose
EP3458079A4 (fr) Compositions et méthodes pour le traitement de l'acné
EP3773633A4 (fr) Méthodes de traitement de glioblastomes
MA45997A (fr) Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d
EP3007722A4 (fr) Méthodes de traitement de l'hypotension
EP3402883A4 (fr) Compositions et méthodes pour le séquençage d'acides nucléiques
EP3735423A4 (fr) Anticorps monoclonal néo-201 pour le traitement des carcinomes humains